SCHEMBL18201252

SCHEMBL18201252

c1ccc(-c2nc(-c3ccccc3)nc(-c3ncc(-c4nc5ccccc5c5c4ccc4ccccc45)c4ccccc34)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ATM Q13315 2/20 0.39
PDE5A O76074 3/20 0.35
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
GPR3 P46089 1/20 0.34
ABCG2 Q9UNQ0 3/20 0.34
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
MAPK1 P28482 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18200888 0.93 MEN1 (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200889 0.92 NPC1 (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200887 0.91 ALDH1A1 (0.44) MAPTSMN1; SMN2LMNARAB9AMEN1
SCHEMBL18200868 0.90 ADORA2A (0.39) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200805 0.90 KDM4E (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18201218 0.90 MAPT (0.43) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200903 0.89 ADORA2A (0.41) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200874 0.89 MAPT (0.34) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18201254 0.88 MAPT (0.42) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18347071 0.88 MAPT (0.42) MAPTSMN1; SMN2NPC1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MAPT 1937/4885SMN1; SMN2 3944/4885NPC1 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.